Diligence memo · auto-generated · as of July 2, 2026
Markman Biologics Corp
Markman Biologics Corp looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Markman Biologics Corp operates in Biotechnology, based in LAS VEGAS.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Markman Biologics Corp has raised $6.5M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $5.0M on 2021-08-25.
Most recent recorded round closed around 2021-08-25.
Valuation (modeled)modeled
Provath models Markman Biologics Corp at approximately $104M (range $5.5M–$433M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.57× the median modeled value of Series A Biotechnology companies in 2019–2021 (216 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 11 months.
Last raise 4.9 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 4.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 48% of Biotechnology peers (4293 compared).
Modeled value ranks above 59% of those peers.
Closest niche peers: TRACT Therapeutics, Inc., TechAccel, LLC, Arrakis Therapeutics, Inc., Trident Labs, Inc., Meissa Vaccines Inc.
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.